Effects of PG-116800, a Matrix Metalloproteinase Inhibitor, to Prevent Left Ventricular Remodeling After Acute Myocardial Infarction - PREMIER

Description:

The goal of the trial was to evaluate treatment with a matrix metalloproteinase (MMP) inhibitor, PG-116800, compared with placebo, among patients with ST elevation myocardial infarction (MI) and signs of heart failure.